A robust paradigm of finding the maximum tolerated dose in phase I cancer clinical trials with application to IL-21 denenicokin
PDF
PDF format is widely accepted and good for printing.
PDF-1(1.65 MB)

Citation & Export
Hide

Simple citation

Young, Tina Chang. A robust paradigm of finding the maximum tolerated dose in phase I cancer clinical trials with application to IL-21 denenicokin. Retrieved from https://doi.org/doi:10.7282/T3KW5JZD

Export

Statistics
Hide